We found 2 unpublished pathways
in the Duchenne cascade
A computational disease cascade analysis of DMD identified 2 novel findings ahead of published literature, confirmed 15 known targets, and surfaced 3 repurposable FDA-approved compounds.
The PHYSIM Platform: A deterministic computational physics platform. Governed by strict mathematical laws, the system maps the entire human genome across every known disease to compute biological certainty, not generative probability. AI serves only as our translator — the core analysis is reproducible, auditable, and deterministic.
This does not replace the laboratory — it de-risks before you get there. Instead of screening thousands of candidates blindly, the system narrows the search space to a focused set of computationally validated targets worth testing. Each finding on this page is a possible new discovery — a possible path toward helping patients — that deserves rigorous experimental validation.
How Duchenne propagates — and where to intervene
The analysis maps the full failure cascade from the primary dystrophin defect through secondary damage pathways to terminal fibrosis. Each node is a validated intervention point.
⚡ = Novel finding — identified computationally, ahead of published literature. 0 PubMed papers connecting these genes to DMD in this context.
2 pathways the literature hasn't connected to Duchenne
These findings emerged from the computational cascade analysis. Both represent potential therapeutic targets with existing, testable interventions.
FGGY → Ribitol → α-Dystroglycan Glycosylation
FGGY encodes a carbohydrate kinase that produces ribitol-5-phosphate — the direct substrate for ISPD, which builds the glycan chain anchoring α-dystroglycan to the ECM.
In metabolically stressed DMD muscle, FGGY downregulation may impair this glycosylation, accelerating sarcolemmal detachment beyond the primary dystrophin defect.
FGB → Fibrin Polymerization Rate → ECM Rigidity
FGB (fibrinogen β-chain) controls the polymerization rate of fibrin clot formation via its N-terminal fibrinopeptide B.
In dystrophic muscle, accelerated FGB-driven fibrin polymerization may create a more rigid ECM that impairs muscle regeneration — a fibrotic mechanism independent of the TGF-β pathway.
What we produce. PHYSIM generates Computational Disease Analysis (CDA) reports — pre-clinical computational investigations that map disease pathways, identify repurposable FDA-approved compounds, and surface novel molecular candidates. Each report is a commissioned, disease-specific analysis built from the platform’s complete structural knowledge of 20,000+ human genes and 10,000+ mapped diseases.
3 compounds the analysis confirmed — you already know them
These FDA-approved or late-stage drugs were independently identified through the cascade analysis, validating the method against established clinical knowledge.
When these interventions matter in DMD progression
The cascade follows a temporal sequence. Early intervention at upstream nodes prevents downstream damage accumulation.
DMD gene defect → dystrophin absence
Primary genetic event. Gene therapy (ELEVIDYS) and exon skipping target this stage directly.
Sarcolemmal instability → calcium influx → CAPN1 activation
Secondary necrosis cascade begins. Calpain inhibitors (SNJ-1945) protect structural proteins from degradation.
⚡ FGGY downregulation → impaired α-dystroglycan glycosylation
Metabolic stress reduces ribitol-5P availability. Glycosylation weakening accelerates ECM detachment. Ribitol supplementation could intervene here.
Fibrinogen extravasation → macrophage activation → TGF-β fibrosis
FGA/FGG drive the fibrotic replacement of muscle. Losartan and pamrevlumab target this stage.
⚡ FGB-driven ECM rigidity → impaired regeneration
Independent of TGF-β. Fibrin polymerization rate hardens the scar matrix. Defibrotide is a candidate for investigation.
Loss of ambulation → cardiac/respiratory compromise
Multi-target intervention across the cascade may delay progression to this stage.
"Time is something our boys do not have. Every day without progress is a day we can't get back."
— Parent Project Muscular Dystrophy
Commission a Computational Disease Analysis
We produce pre-clinical CDA reports that map your disease of interest across the full human genome — identifying novel pathways, repurposable compounds, and structural drug targets before you enter the lab. Tell us what you’re working on.
Start a Conversation →